Jaguar Health, Inc. (NASDAQ:JAGX) shares dipped -22.63% to $0.82 in the premarket session after the report that the Firm has reached an agreement with a secured lender a non-dilutive royalty funding deal.In the agreement, Jaguar will sell a royalty interest to the Lender for an aggregate purchase price of $6 million, entitling the Lender to obtain 2.0x the royalty purchase price of Mytesi and Lechlemer’s potential royalties and others upwards of $6 million.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Jaguar plans to use the proceeds to finance the Company’s research pipeline-related regulatory operations, including ongoing funding patient registration for the cornerstone phase 3 trial of crofelemer for diarrhea prophylaxis in adult cancer patients undergoing targeted therapy launched last October by the wholly-owned subsidiary of the Company, Napo Pharmaceuticals, Inc. (Napo). This $6 million royalty funding deal follows an earlier $6 million royalty transaction with a Lender partner concluded in October 2020.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Read More
Moreover, we reported yesterday that Jaguar Health (JAGX) announced the results of the special meeting of Jaguar stockholders held on December 9, 2020.
